• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany
CONCLUSION: Real-world experiences indicate that favorable oncologic outcomes can be achieved with CAB especially regarding PSA-response and OS even in the fourth line or later in patients with mCRPC.PMID:36244915 | DOI:10.1016/j.urolonc.2022.09.011
Source: Urologic Oncology - October 16, 2022 Category: Urology & Nephrology Authors: Mike Wenzel Angelika Borkowetz Verena Lieb Manuela A Hoffmann Hendrik Borgmann Thomas H öfner Robert Dotzauer Manuel Neuberger Thomas S Worst Jost von Hardenberg Johannes Linxweiler Niklas Kl ümper Source Type: research

Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort
CONCLUSIONS: Pre-treatment mGPS seems a promising prognostic biomarker. A combination of mGPS, NLR and further routine markers (e.g., Hb and AP) could yield optimized stratification for treatment selection. Further prospective and multicentric assessment is needed.PMID:35939112 | DOI:10.1007/s00432-022-04220-w
Source: Clinical Prostate Cancer - August 8, 2022 Category: Cancer & Oncology Authors: Manuel Neuberger Nora Goly Janina Skladny Veronica Milczynski Christel Wei ß Frederik Wessels Katja Nitschke Britta Gr üne Cael án M Haney Friedrich Hartung Jonas Herrmann Jonas Jarczyk Karl F Kowalewski Frank Waldbillig Maximilian C Kriegmair Niklas W Source Type: research

The Treatment of Metastatic, Hormone-Sensitive Prostatic Carcinoma
CONCLUSION: The treatment of mHSPC is constantly changing. Phase III trials that are now in the recruitment stage, as well as our continually improving understanding of the underlying molecular-pathological mechanisms, will be altering the treatment landscape still further in the years to come.PMID:35912436 | DOI:10.3238/arztebl.m2022.0294
Source: Deutsches Arzteblatt International - August 1, 2022 Category: General Medicine Authors: Axel S Merseburger Laura-Maria Krabbe Bernd Joachim Krause Dirk B öhmer Sven Perner Gunhild von Amsberg Source Type: research

Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan
CONCLUSION: Real-world mCRPC treatment patterns largely reflected national guidelines. It is expected that guidelines and treatment patterns will change with the development of new treatment options.PMID:35316501 | DOI:10.1007/s12325-022-02073-w
Source: Adv Data - March 22, 2022 Category: Epidemiology Authors: Andrea Leith Jeri Kim Amanda Ribbands Emily Clayton Lingfeng Yang Sameer R Ghate Source Type: research

PSMA radioligand therapy in patients with advanced prostate cancer.
CONCLUSIONS: Despite the promising preliminary results of 177Lu-PSMA-RLT, the efficacy results of VISION need to be awaited prior to using the therapy outside of compassionate use provisions. PMID: 32333064 [PubMed - as supplied by publisher]
Source: Nuklearmedizin - April 23, 2020 Category: Radiology Authors: Bögemann M, Herrmann K, Radtke JP, Rahbar K Tags: Urologe A Source Type: research

Basket Trials for Intractable Cancer
This study has made a significant impact on clinical practice in cancer patients harboring the TRK translocation, and also illustrates the potential for future advancements in drug development and clinical trials of cancers harboring rare genomic alterations (50). Second, a basket trial may allow screening for potential efficacy across multiple tumor types in order to guide more traditional, disease-specific, follow-up studies. The goal of some basket trials is to obtain an overall assessment of the drug with pooled histologies; in such trials, subsequent analyses are straightforward, and are comparable to those in standa...
Source: Frontiers in Oncology - April 11, 2019 Category: Cancer & Oncology Source Type: research